General
Preferred name
MIDOSTAURIN
Synonyms
PKC-412, CGP-41251, NVP-PKC412 ()
CGP41231 ()
PKC 412 ()
RYDAPT ()
CGP 41251 ()
CGP-41251 ()
NSC-656576 ()
NVP-PKC412 ()
PKC-412 ()
PKC412 ()
P&D ID
PD021374
CAS
120685-11-2
Tags
available
drug
Approved by
EMA
FDA
First approval
2017
Drug Status
investigational
approved
Drug indication
Acute myeloid leukaemia
Chronic myelomonocytic leukaemia
Systemic mastocytosis
Colorectal cancer
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Midostaurin is an analogue of , and was originally described as a PKC inhibitor . It was later reported as an inhibitor of fms-related tyrosine kinase 3 (FLT3) . (GtoPdb)
MOA It potently inhibits multiple receptor tyrosine kinases. Midostaurin and its major active metabolites CGP62221 and CGP52421 inhibit the activity of protein kinase C alpha (PKCalpha), VEGFR2, KIT, PDGFR and WT and/or mutant FLT3 tyrosine kinases. Inhibition of FLT3 receptor signalling cascades induces apoptosis of target leukemia cells expressing target receptors and mast cells, in addition to its antiproliferative activity toward multiple cancer cell lines [A19108]. ; Midostaurin also interacts with organic anion transporter (OATP) 1A1 and multidrug resistance protein (MRP)-2 according to preliminary in vitro studies.
DESCRIPTION On april 28 , 2017, the FDA approved midostaurin to treat acute myeloid leukemia (PKIDB)
Cell lines
656
Organisms
1
Compound Sets
24
AdooQ Bioactive Compound Library
A12650
Cayman Chemical Bioactives
10459
ChEMBL Approved Drugs
CHEMBL608533
ChEMBL Drugs
CHEMBL608533
Clinical kinase drugs
Drug Repurposing Hub
DrugBank
DB06595
DrugBank Approved Drugs
DB06595
DrugCentral
5231
DrugCentral Approved Drugs
5231
DrugMAP
DMI6E0R
DrugMAP Approved Drugs
DMI6E0R
EU-OPENSCREEN Bioactive Compound Library
EOS101820
Guide to Pharmacology
5702
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL608533
LSP-OptimalKinase library (Laboratory of Systems Pharmacology)
CHEMBL608533
MedChem Express Bioactive Compound Library
HY-10230
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
ID912S5VON
Novartis Chemogenetic Library (NIBR MoA Box)
PKIDB
Reference compounds for characterizing cellular injury in high-content cellular morphology assays
ReFrame library
ZINC Tool Compounds
ZINC000100013130
External IDs
38
Properties
(calculated by RDKit )
Molecular Weight
570.23
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
1
Rotatable Bonds
3
Ring Count
9
Aromatic Ring Count
6
cLogP
5.91
TPSA
77.73
Fraction CSP3
0.26
Chiral centers
4.0
Largest ring
7.0
QED
0.29
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Targets
PRKCA,PRKCB,PRKCG,SYK,KDR,AKT1,AKT2,AKT3,PRKACA,PRKACB,PRKACG,KIT,FGR,SRC,FLT3,PDGFRB,FLT1,KDR
Member status
member
MOA
Inhibitors of Signal Transduction Pathways
Flt3 (FLK2/STK1) Inhibitors
Protein Kinase C (PKC) Inhibitors
Angiogenesis Inhibitors
FLT3 inhibitor, KIT inhibitor, PKC inhibitor
Target
FLT3, PRKCG
c-Kit
NO Synthase
PKC
VEGFR
Indication
acute myeloid leukemia (AML)
Cellular injury category
Kinase
Biosynthetic Origin
Alkaloid
Therapeutic Indication
Anticancer
Therapeutic Class
Anticancer Agents
Pathway
Apoptosis
Epigenetics
Immunology/Inflammation
Protein Tyrosine Kinase/RTK
TGF-beta/Smad
Source data